Blogs
Healthcare and Medtech Research Reports
Articles
The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals diagnosed with different types of cancers each year. In 2022, regulators will continue to evaluate new oncology therapies and also the ones approved for other indications for unmet needs in the growing, aging cancer community. The oncology drug pipeline consists of some highly anticipated therapies, including Imbruvica + Venclexta, Kymriah, Yescarta, Navitoclax, and many more. These oncology drugs represent new drug classes, significant changes in clinical practice, and sign...
Explore More...